GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.